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Background: An analysis of intracranial hemorrhage (ICH) in a national sample of autosomal dominant polycystic
kidney disease (ADPKD) patients receiving long-term dialysis has not been reported. It is often assumed that
patients with ADPKD are not at increased risk of ICH after starting dialysis. We hypothesized that patients with
ADPKD would have a higher subsequent risk of ICH even after the start of chronic dialysis.
Methods: Retrospective cohort study of Medicare primary patients with and without ADPKD in the United States
Renal Data System (USRDS), initiated on chronic dialysis or transplanted between 1 January 1999 and 3 July 2009,
and followed until 31 December 2009. Covariates included age, gender, race, prior stroke, diabetes mellitus, dialysis
modality, body mass index, serum albumin and other co-morbid conditions from the Medical Evidence Form.
Primary outcome was ICH, based on inpatient and outpatient Medicare claims, and all-cause mortality. Kaplan-Meier
analysis was used for unadjusted assessment of time to events. Cox regression was used for assessment of factors
associated with ICH and mortality. We performed competing risk regression using kidney transplant and death as
competing risks. Kidney transplant was also modeled as a time-dependent covariate in Cox regression.
Results: Competing risk regression demonstrated that ADPKD had a subhazard ratio 2.97 for ICH (95% CI 2.27-3.89).
Adjusted Cox analysis showed that ADPKD patients had an AHR for death of 0.59 vs. non-ADPKD patients
(95% CI 0.57-0.61).
Conclusions: ADPKD is a significant risk factor for ICH among patients on maintenance dialysis. Our Medicare primary
cohort was older than in previous studies of intracranial aneurysm rupture among ADPKD patients. There are also
limitations inherent to using the USRDS database.
Keywords: Intracranial hemorrhage, Intracranial aneurysm, Autosomal dominant polycystic kidney disease, Stroke, Dialysis,
USRDS, Competing riskBackground
Autosomal dominant polycystic kidney disease (ADPKD)
is one of the most common single gene hereditary disor-
ders, occurring in about 1 in every 400–1000 live births
[1-3]. It is associated with renal, hepatic, and pancreatic
cysts, valvular heart disease, diverticular disease, and intra-
cranial aneurysms [4]. The genes responsible, PKD1 and
PKD2, respectively, appear to have equivalent expression
of intracranial aneurysms and play a direct pathogenetic* Correspondence: kevin.c.abbott.mil@health.mil
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unless otherwise stated.role in aneurysm formation, [5,6]. A ruptured intracranial
aneurysm is a potentially life-threatening complication of
ADPKD, associated with considerable morbidity and mor-
tality [7-10]. Intracranial aneurysm prevalence in ADPKD
ranges from 4% to as high as 41% with a positive family
history, increasing with age; rates per person-years are not
available [2,11-14]. Aneurysmal subarachnoid hemorrhage
(SAH) has a 30-day mortality rate of 45%. The survivors
of these strokes have about a 30% chance of moderate
or severe disability [15]. In comparison, in the general U.S.
population the incidence of subarachnoid hemorrhage
is 9–20 per 100,000 person-years (PY), with 30-day mor-
tality of 35%-52%, [16,17]. The overall total intracranial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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100,000 PY [18]. In the general population, risk factors for
ICH include male gender, older age, Asian ethnicity [19],
and in the U.S., African American (AA) ethnicity [20]. The
most important etiologies for ICH in the general popula-
tion are hypertension (usually leading to hemorrhage in
deep structures) and cerebral amyloid angiopathy (CAA)
[21]. CAA is less likely related to blood pressure but more
with older age, and associated ICH tends to occur in lobar
regions [22]. Chief among genetic factors contributing to
ICH is apolipoprotein E (APOE) gene and ɛ2 and ɛ4
alleles [23]. ADPKD is prominent among genetic con-
tributors to SAH, along with first degree family history,
Marfan’s syndrome and Ehlers-Danlos syndrome [16].
Patients with end-stage renal disease (ESRD) may be
at increased risk of hemorrhagic stroke, due to hyperten-
sion, bleeding diatheses, and routine administration of
heparin during hemodialysis. A recent USRDS study by
Seliger reported an incidence ICH in hemodialysis pa-
tients was about 5 per 1000 PY [18].
There is little recent data regarding the risk of ICH in
ADPKD patients receiving long-term renal replacement
therapy. The objective of this study is to delineate differ-
ences in risk of ICH among the ADPKD vs. non-ADPKD




We conducted a retrospective cohort study using the
USRDS database. Because the identity of individual sub-
jects is not disclosed and not obtainable from the
USRDS datasets, and due to the substanial number of
cases studied, individual consent was not obtained and
the study was approved as exempt review by the Walter
Reed National Military Medical Center Institutional
Review Board. The variables included in the USRDS
standard analysis files (SAFs), as well as data collection
methods and validation studies, are listed at the USRDS
website, under ‘Researcher’s Guide to the USRDS Data-
base’, Section E, ‘Contents of all the SAFs’ (Standard
Analysis Files), and published in the USRDS (www.
usrds.org). The demographics of the dialysis population
have been previously described [24]. The files SAF.PA-
TIENTS were used as the primary dataset, including
primary disease causing ESRD (PDIS) and cause and
date of patient death. We defined the ADPKD cohort
using the code (75313) for “polycystic kidneys, adult
type (dominant)” from the PDIS variable. SAF.MEDE-
VID was used for additional information coded in the
Medical Evidence Form starting in 1995, modified in
2005, and has highest sensitivity and specificity for car-
diovascular outcomes [25]. We included patients who
were initiated on chronic dialysis or transplanted from 1January 1999 to 3 July 2009, followed until 31 Dec 2009
for Medicare claims of ICH or 2 December 2010 for
outcomes of death (since Medicare related claims lag a
year behind ascertainment of death). Study eligibility
was restricted to patients with complete identifying and
demographic information as well as evidence of Medicare
as primary payer from the date of starting ESRD, as indi-
cated from the PAYHIST file. This restriction was necessary
in order to ensure accurate ascertainment of Medicare
claims, which might not be reported in patients covered
primarily by an insurer other than Medicare. Because
ADPKD patients are significantly younger (mean age
54 years per USRDS report above) than patients with
other causes of ESRD (mean age 64 years), restriction of
our cohort to those with Medicare primary insurance,
resulted in our including only 27% of total patients with
ADPKD.
Outcome variables
Our primary outcome, the incidence of ICH, was based on
assessment of Medicare claims (either one inpatient claim
or at least two outpatient claims) for any of the following
ICD9 codes: 1) 430 “subarachnoid hemorrhage” 2) 432
“other and unspecified intracranial hemorrhage”. More
specifically, ICD 430 included meningeal hemorrhage, rup-
tured berry aneurysm, and congenital aneurysm not other-
wise specified (NOS), and excluded syphilitic cerebral
aneurysm (094.87). ICD 432 included non-traumatic extra-
dural/epidural hemorrhage (432.0), subdural hemorrhage
(SDH) (432.1), and unspecified intracranial hemorrhage
(432.9). We used diagnosis 1 and 2 as a composite out-
come. The secondary outcome was all-cause mortality.
Other predictor variables
Covariates included age at initiation of dialysis, gender,
race (AA vs. non-AA), diabetes as a co-morbid condition,
dialysis modality (for at least 60 days, from the treatment
history files), body mass index, serum albumin and other
co-morbid conditions from the Medical Evidence Form
known to be associated with the outcomes, particularly
prior history of stroke. Primary analysis included patients
with prior history of cerebrovascular disease (cerebrovas-
cular accident and transient ischemic attack) as a covari-
ate. Furthermore, sensitivity analysis was conducted in a
cohort of patients without a prior history of cerebrovascu-
lar disease.
Statistical analysis
Analyses were performed using Stata 12.1 SE (Stata Corp,
College Station, TX). Chi-square test (with Fisher exact
test used for instances of fewer than 5 subjects) was used
for assessment of categorical outcomes, Student’s t-test
used for continuous outcomes, and non-parametric tests
(Kruskal-Wallis) used for non-normal distributions.
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ment of time to events. Cox regression was used for as-
sessment of factors associated with ICH and mortality.
Both graphical and formal methods were used to test
the proportional hazards assumption. Model building
used “forced” entry to account for factors known to be
associated with outcomes based on existing literature,
to avoid exclusion of such factors in stepwise models.
Because ICH was a nonfatal outcome and could be pre-
cluded by the occurrence of death, death was also mod-
eled as a competing risk in competing risk regression.
Receipt of kidney transplant did not preclude the occur-
rence of intracranial hemorrhage but certainly could
modify its occurrence due to selection and other factors.
It was modeled both as a competing event in competing
risk regression and a segmented time-dependent covari-
ate in Cox regression (not modeled as a segmented
time-dependent covariate in competing risks regression as
this was too computationally intensive for our population
size). Missing values for the variables serum albumin and
body mass index (BMI, in kg/m2) were addressed by mul-
tiple imputation via linear regression method (STATA
12.1 multiple imputation module).
Results
We identified 512,772 Medicare primary patients in the
USRDS who were initiated on chronic dialysis or kidney
transplantation between January 1, 1999 and July 2009,
followed until 31 December 2009. Of these, a total of
8,793 patients (1.71%) developed ICH during the study
period, and 6,749 (1.32% of total, or 1.42% of patients
with non-missing causes of ESRD) had ADPKD as the
primary cause of ESRD. For 2007 and 2008, our primary
Medicare cohort included 27% and 26% respectively of
all ESRD patients reported to the USRDS who had a pri-
mary diagnosis of ADPKD. Our primary Medicare co-
hort included 44% of all ESRD patients reported to the
USRDS during that time. Thus, as expected, our primary
Medicare cohort patients were significantly older than the
total cohort, and less likely to have a primary diagnosis of
ADPKD. Other demographic distinctions were not signifi-
cant except for a higher percentage of black race.
Table 1 shows the unadjusted characteristics of pa-
tients in the ADPKD and non-ADPKD cohort. As com-
pared to other causes of ESRD, patients with ADPKD
were younger at start of dialysis and were more likely to
be on peritoneal dialysis and to have received a kidney
transplant. Other factors that were significantly associated
with ADPKD included hypertension, tobacco use, higher
mean hemoglobin, higher mean serum albumin, higher
mean total cholesterol, higher mean low density lipopro-
tein (LDL) and BMI. Factors associated with non-ADPKD
cohort were AA race, congestive heart failure, atheroscler-
otic heart disease, cerebrovascular disease, peripheralvascular disease, diabetes mellitus, chronic obstructive
pulmonary disease, and alcohol dependence.
Unadjusted analyses showed that 3.67% of ADPKD pa-
tients developed ICH vs 1.96% of non-ADPKD patients
(p < 0.001) (Figure 1). ADPKD and non-ADPKD patients
had 10.93 (95% CI 9.64-12.39) and 7.51 (95% CI 7.35-7.67)
episodes of ICH per 1000 PY, respectively. For every 51.5
patients with ADPKD, there was one additional case of
ICH, compared to patients without ADPKD (95% CI, 41.9-
67.0). 0.71% of ADPKD patients had ruptured berry
aneurysm vs 0.33% of non-ADPKD patients (p < 0.001).
The mean time to ruptured berry aneurysm was 3.70 years
from initiation of chronic dialysis in ADPKD patients vs
2.36 years for non-ADPKD patients (p < 0.001). All-cause
mortality was 45.41% among ADPKD patients vs 71.89%
among non-ADPKD patients (p < 0.001). Among the
ADPKD cohort, those patients with ICH had a cumulative
mortality risk of 64.08% vs. 44.71% among those without
ICH (p <0.001) (Figure 2). Among the non-ADPKD cohort,
those patients with ICH had a higher mortality risk of
82.42% vs 71.71% among those without ICH (p <0.001).
Table 2 shows the results of the adjusted Cox regression
analysis of the factors associated with development of
ICH. ADPKD was a significant predictor for ICH with an
adjusted hazard ratio (AHR) of 1.63. After exclusion of pa-
tients who had a history of cerebrovascular disease includ-
ing cerebrovascular accident (CVA) and transient ischemic
attack (TIA), the risk of ICH among ADPKD patients still
remained significant with an AHR 1.59 (95% CI 1.39-1.84).
Other significant risk factors included age, year of first
ESRD service, male gender and AA race. Furthermore,
hemodialysis represented a significant risk factor for ICH as
compared to peritoneal dialysis (AHR 1.32). Diabetes melli-
tus, hypertension, atherosclerotic heart disease, congestive
heart failure, peripheral vascular disease, chronic obstruct-
ive pulmonary disease tobacco use and alcohol dependence
were not significantly associated with ICH.
In a separate Cox model, we included imputed variables
of serum albumin and BMI as covariates, given significant
missing values (68.7% of serum albumin values and 60.3%
of BMI values missing). With the imputed serum albumin
as a covariate, ADPKD had an AHR 1.64 (95% CI 1.43-
1.87) for ICH. In a similar analysis with the imputed BMI
as a covariate, ADPKD had an AHR 1.62 (95% CI 1.42-
1.85) for ICH.
Given that kidney transplant and death represented
competing risks for the development of ICH, we per-
formed competing risk regression which demonstrated
that ADPKD had a subhazard ratio of 2.97 for ICH (vs.
non-ADPKD) (Table 3). Furthermore, receipt of a kid-
ney transplant, when modeled as a time-dependent co-
variate in Cox regression analysis, demonstrated an
AHR of 0.77 for ICH in ADPKD patients during the
post-transplant period (vs. pre-transplant period) (95%
Table 1 Baseline demographic and comorbidity characteristics of study cohort from January 1999 to July 2009
Variables ADPKD Non-ADPKD P-value
(n = 6,749) (n = 506,023)
Gender 0.426
Male 3,551 (52.6) 268,709 (53.1)
Female 3,198 (47.4) 237,314 (46.9)
Race <0.001
AA 848 (12.6) 123,256 (24.4)
Non-AA 5,901 (87.4) 382,767 (75.6)
Mean age at start of dialysis (yr) 65.30 70.20 < 0.001
(95% CI 65.01-65.64) (95% CI 70.21-70.28)
Dialysis modality <0.001
Hemodialysis 4,636 (79.4) 412,185 (92.4)
Peritoneal dialysis 1,206 (20.6) 34,163 (7.7)
Receipt of kidney transplant 1,784 (26.4) 24,743 (4.9) <0.001
CHF 1,002 (14.9) 197,017 (39.6) <0.001
Atherosclerotic heart disease 1,144 (17.0) 152,623 (30.7) <0.001
Cerebrovascular disease (CVA, TIA) 541 (8.0) 59,859 (12.0) <0.001
Peripheral vascular disease 452 (6.7) 91,337 (18.4) <0.001
Hypertension 5,682 (84.4) 405,168 (81.4) <0.001
Diabetes mellitus 480 (7.1) 212,998 (42.8) <0.001
COPD 470 (7.0) 55,199 (11.1) <0.001
Tobacco use 426 (6.3) 23,207 (4.7) <0.001
Alcohol dependence 43 (0.6) 4,862 (1.0) 0.005
Mean hemoglobin (g/dL) 10.81 10.16 <0.001
(95% CI 10.75-10.87) (95% CI 10.16-10.17)
Mean serum albumin (g/dL) 3.66 3.13 <0.001
(95% CI 3.63-3.69) (95% CI 3.13-3.14)
Mean total cholesterol (mg/dL) 159.50 151.16 <0.001
(95% CI 155.86-163.14) (95% CI 150.68-151.64)
Mean low density lipoprotein (mg/dL) 92.61 87.41 0.017
(95% CI 88.39-96.83) (95% CI 86.85-87.96)
Mean body mass index (kg/m2) 27.10 28.34 <0.001
(95% CI 26.83-27.37) (95% CI 28.30-28.37)
Data are n (%) or mean ± standard deviation.
Univariate analyses were performed with Chi-square testing for categorical variables (Fisher’s exact test used for violations of Cochran’s assumptions) and Student's
t-test for continuous variables (Mann–Whitney test used for non-normally distributed variables).
ADPKD: autosomal dominant polycystic kidney disease; AA: African American; COPD: chronic obstructive pulmonary disease; CHF: congestive heart failure; CVA:
cerebrovascular accident; TIA: transient ischemic attack.
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race, hemodialysis vs peritoneal dialysis, year of starting
dialysis vs more recent year, and hypertension.
Adjusted Cox regression demonstrated that ADPKD pa-
tients had an AHR of death of 0.59 vs non-ADPKD pa-
tients (95% CI 0.57-0.61). AHRs for death among ADPKD
patients were similar when Cox regression analyses were
performed across specific age groups: AHR 0.45 (95% CI
0.31-0.64) for the 20–40 year-old group; AHR 0.49 (95%CI 0.45-0.55) for the 40–60 year-old group; AHR 0.57
(95% CI 0.55-0.60) for the 60–80 year-old group.
Discussion
In our competing risk model, the ICH incidence was sig-
nificantly higher in the ADPKD-patients vs. non-ADPKD-
patients with an adjusted subhazard ratio of 2.97. Despite
the significantly greater relative risk of ICH among ADPKD
patients, however, their absolute risk of ICH (10.9/1000 PY)
Figure 1 Proportion of patients starting chronic dialysis
therapy in the United States who developed intracranial
hemorrhage (ICH), starting with the first date of dialysis.
Patients with autosomal dominant polycystic kidney disease
(ADPKD) as cause of the end stage kidney disease had a significantly
higher incidence of ICH, especially after the third year on dialysis.
Table 2 Cox proportional hazard model to evaluate for









Age at start of dialysis 1.02 <0.001 1.02-1.02
Year of starting dialysis
(vs. more recent year)
1.07 <0.001 1.06-1.08
Gender (male vs female) 1.05 0.04 1.00-1.09
Race (AA vs non-AA) 1.06 0.015 1.01-1.12
Diabetes mellitus 0.99 0.717 0.95-1.04
Alcohol dependence 1.10 0.412 0.87-1.40




Hypertension 0.95 0.109 0.90-1.01
Atherosclerotic heart disease 0.97 0.207 0.92-1.02
Congestive heart failure 1.04 0.099 0.99-1.09




ADPKD: autosomal dominant polycystic kidney disease; AA: African-American
CVA: cerebrovascular accident; TIA: transient ischemic attack.
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(7.5/1000 PY), resulting in a relatively high number of pa-
tients (29.4 using incidence density) who would need to be
followed to observe one additional case of ICH, compared
to patients without ADPKD. In adjusted Cox analysis,
ADPKD was a significant predictor of ICH in ESRD pa-
tients on renal replacement therapy. We also observed that
the increased risk of ICH associated with ADPKD did not
manifest until approximately three years on dialysis. This
could be related to the relatively older age of the ADPKD
cohort (65.3 years at initiation of dialysis). Older age was a
significant risk factor for ICH in our study and thus consist-
ent with the finding of higher risk of ICH among ADPKDFigure 2 Proportion of patients with ADPKD who died,
comparing those who did not experience ICH (starting at the
date of first dialysis) with those who experienced ICH (starting
with the date of ICH). Those with ICH had significantly higher
subsequent risk of death.patients with accrued time on renal replacement therapy.
Also, a significantly higher proportion of ADPKD patients
received a kidney transplant compared to the non-ADPKD
patients (26.4% vs. 4.9%, respectively), and based on our
finding of lower risk of ICH post-transplant vs. pretrans-
plant period, we may speculate that a kidney transplant
had an initial mitigating effect on the risk of ICH among
ADPKD patients.
ICH incidence increases with age, tobacco use, hyper-
tension, heavy ethanol use, and female sex after age 60
[26]. However, there has been no large study comparing
the incidence and risk factors for ICH in ADPKD patients
vs. non-ADPKD patients on renal replacement therapy. In
a previous USRDS study by Seliger et al., ADPKD was not
reported as a significant risk factor for hemorrhagic stroke,
with an AHR of 2.55 (p = 0.07) [27]. This study, conducted
before 1997, was approximately 13,000 patients with 710
ADPKD patients and 910 strokes. For a relatively rare diag-
nosis, such as ADPKD, these findings are not inconsistent
allowing for differences in sample size and methods. The
Seliger study included important information on blood
pressure at dialysis initiation, but did not use competing
risks regression to treat death and kidney transplant as
competing events.
The ADPKD cohort in our study had a lower mortality
rate compared to the non-ADPKD cohort, even when
age-matched. This is in contrast to a previous study by
Table 3 Competing risks regression model to evaluate for
predictive variables of intracranial hemorrhage, with





ADPKD (vs. non-ADPKD) 2.97 <0.001 2.27-3.89
Age at start of dialysis 0.98 <0.001 0.98-0.99
Gender (male vs. female) 0.99 0.952 0.89-1.11




Year of starting dialysis
(vs more recent year)
1.39 <0.001 1.36-1.42
Diabetes mellitus 0.76 <0.001 0.68-0.85
COPD 0.66 <0.001 0.54-0.82
Hypertension 1.23 0.008 1.06-1.43







Tobacco use 0.78 0.079 0.59-1.03
Alcohol dependence 0.89 0.679 0.50-1.58
Serum albumin < 3gm/dL 0.93 0.326 0.80-1.08
BMI < 20 kg/m2 0.80 0.091 0.63-1.04
ADPKD: autosomal dominant polycystic kidney disease; AA: African-American;
COPD: chronic obstructive pulmonary disease; BMI: body mass index.
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hemodialysis in which there was no statistically significant
difference in mortality [28]. However, the Pirson study
was not sufficiently powered to detect a significant mortal-
ity difference, as there were only 50 patients in each arm.
It is also possible that there is less risk for atherosclerotic
cardiovascular disease among patients with ADPKD with
ESRD compared to those with ESRD due to other etiolo-
gies. In our study, the non-ADPKD cohort had a higher
prevalence of CHF, atherosclerotic heart disease, periph-
eral vascular disease, cerebrovascular accident, and had a
higher BMI and lower serum albumin, all suggestive of a
less healthy patient population compared to the ADPKD
cohort.
There is a 35-55% combined case mortality and morbid-
ity following intracerebral aneurysm rupture in ADPKD
patients [12,29]. Not surprisingly, within our ADPKD co-
hort, those with ICH had a higher death rate compared to
those without ICH.
AA race was a significant risk factor for ICH in our
study. This is consistent with other literature where the in-
cidence rate ratios relative to whites ranged from 1.4-1.8
among non-hemodialysis patients [30-32]. In the USRDS
study by Seliger mentioned above, black patients on
hemodialysis who did not have cardiovascular disease hadtwice the rate of hemorrhagic stroke compared to the
white cohort [21].
ADPKD patients who underwent renal transplant-
ation had a lower risk of ICH as compared to those who
remained on dialysis, possibly reflecting pre-transplant
screening and selection against or intervention in pa-
tients with aneurysms. ADPKD patients who were on
hemodialysis had a higher risk of ICH compared to
those who were on peritoneal dialysis. These findings
may be explained by the blood pressure fluctuations as-
sociated with extracorporealization during hemodialysis,
as well as required systemic anticoagulation. This is some-
what consistent with the USRDS study by Seliger men-
tioned above. In that study, receiving a transplant was
associated with a lower risk of cerebrovascular event
but there was no significant risk reduction with periton-
eal dialysis compared to hemodialysis (did not differen-
tiate between hemorrhagic stroke vs ischemic stroke)
[21]. Another USRDS study which looked at subdural
hematoma (ICD 432.1) showed a doubling incidence
from 1991 to 2002 in the hemodialysis cohort but no
significant upward trend for those on peritoneal dialysis
[33]. This study again suggests the potential for intra-
cranial hemorrhage due to blood pressure fluctuations
and anticoagulation associated with hemodialysis.
About 19% of the ADPKD cohort who developed ICH
had a known berry aneurysm, about double that of non-
ADPKD cohort. A previous study of 129 ADPKD patients
who died showed that 11% of them died due to ICH. Of
these, about half had a ruptured intracranial aneurysm
[34]. The prevalence of intracranial aneurysms might have
been even higher than 19% among ADPKD patients who
developed ICH, due to lack of screening. The prevalence
of intracranial aneurysm in ADPKD is about 5-10% based
on 3 prospective trials totaling 266 patients [11,35,36].
However, at least in the general population, the vast ma-
jority of intracranial aneurysms do not rupture [37] and
therefore presumably do not need intervention, making a
screening strategy based on detection of aneurysms prob-
lematic. Patients with PKD1 and PKD2 seem equally likely
to develop intracranial aneurysms, while patients with mu-
tations to the 5' half of PKD1 may more likely have vascu-
lar complications [38]. Screening has been reported and
recommends focus on patients age <30, not applicable to
the current study population [7].
Limitations
There were several limitations with our study. Because
our cohort was limited to Medicare primary recipients,
which was required to strictly ascertain Medicare-defined
outcomes, such as claims for specific diagnoses, the pa-
tients were significantly older than the USRDS population
as a whole, and excluded a disproportionately higher frac-
tion of patients with ADPKD. The USRDS does not have
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of further evaluation for cerebral aneurysm, especially with
a known diagnosis of ADPKD. The USRDS also does not
have information on ADPKD genotype, and we thus can-
not distinguish between genotype PKD1 vs. genotype
PKD2, which generally has a more indolent course than
PKD1, ie later age at diagnosis, and later onset of hyper-
tension and ESRD [39,40]. In any case, it may be even
more impressive that a significant association was seen be-
tween ADPKD and subsequent ICH, as it is often assumed
that ADPKD patients are past their high-risk period for
intracranial events once they have started dialysis.
As a retrospective study, another limitation was the risk
of misclassification. The primary outcome of ICH was
based on ICD-9 codes which are entirely determined by
physician documentation and standard clinical practice.
Because all ADPKD patients are not screened for berry an-
eurysms, but only “high risk” patients, unscreened ADPKD
patients may have an ICH due to intracranial aneurysm
rupture, but may be coded as hemorrhagic CVA due to ap-
pearance on conventional imaging. Thus reliance solely on
the diagnosis of subarachnoid hemorrhage could lead
to under-ascertainment of the true incidence of ruptured
intracranial aneurysms. Conversely, most hemorrhagic
CVA’s in the general population or dialysis population are
likely not related to ruptured intracranial aneurysm. This
may not be the case for patients with ADPKD but the
USRDS does not supply sufficient detail to definitively an-
swer this question. Therefore, we performed sensitivity
analyses of each outcome individually, in addition to the
aggregate outcome, as used by previous investigators
[11,20] and demonstrated similar findings. Due to the
retrospective nature of our analysis, which assesses associ-
ation only and not causality, we cannot account for screen-
ing and other surveillance biases. As noted previously,
patients with ADPKD are more likely to be evaluated for
intracranial aneurysms than patients with other causes of
ESRD. However, the diagnosis of hemorrhagic CVA should
not be susceptible to surveillance bias, which is why we
included it as an outcome. In addition, information on
family history was not available. The risk of ICH is likely
restricted to a subgroup of all patients with ADPKD.
However, this is essentially a type of residual confound-
ing in which the risk of any categorical variable (ie, dia-
betes, hypertension) is not uniformly distributed among
all subjects with the condition, but rather varies accord-
ing to the severity of the condition. This is a common
limitation of all registry data.
Demographically, for purposes of analysis, patients
were considered to be African-American or not. As
discussed earlier, our cohort was older compared to
the mean age at the time of intracranial aneurysm rup-
ture reported among ADPKD patients (65.3 years vs.
41 years).Strengths of the study are its large size and consistency
of findings over many years. The study describes national
physician practice as documented by standard coding
techniques. Single center studies, and even multi-center
studies unless conducted over many years, would not be
large enough to assess differences in the outcomes that
were assessed.
Conclusions
Medicare primary patients with ESRD due to ADPKD
were at independently increased risk of ICH compared to
patients with other causes of ESRD. While the nature
of our analysis cannot entirely exclude issues of misclassi-
fication and surveillance bias, our results strongly suggest
that an increased risk of ICH continues for patients with
ADPKD even after onset of dialysis. Peritoneal dialysis was
associated with a lower risk of ICH which can be po-
tentially explained by the significant blood pressure
fluctuations during hemodialysis as well as use of anti-
coagulants. The significantly lower risk of ICH for
ADPKD patients after kidney transplantation suggests
either that such patients are carefully screened prior to
transplant and/or that remaining on dialysis poses a
greater risk for subsequent ICH.
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